These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 7745698

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
    Rusconi S, La Seta Catamancio S, Sheridan F, Parker D.
    J Clin Virol; 2000 Dec; 19(3):135-42. PubMed ID: 11090748
    [Abstract] [Full Text] [Related]

  • 5. Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.
    Nielsen C, Bruun L, Mathiesen LR, Pedersen C, Gerstoft J.
    AIDS; 1996 Jun; 10(6):625-33. PubMed ID: 8780817
    [Abstract] [Full Text] [Related]

  • 6. Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children.
    Principi N, Marchisio P, Esposito S, Rossi P, Gattinara GC, Galli L, Gabiano C, Zuccotti GV, Orlandi P.
    AIDS Res Hum Retroviruses; 1998 Dec 20; 14(18):1653-9. PubMed ID: 9870319
    [Abstract] [Full Text] [Related]

  • 7. Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors.
    Venturi G, Romano L, Catucci M, Riccio ML, De Milito A, Gonnelli A, Rubino M, Valensin PE, Zazzi M.
    Eur J Clin Microbiol Infect Dis; 1999 Apr 20; 18(4):274-82. PubMed ID: 10385016
    [Abstract] [Full Text] [Related]

  • 8. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine.
    Masquelier B, Pellegrin I, Ruffault A, Ragnaud JM, Morlat P, Michelet C, Doignon F, Biteau N, Fleury HJ.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr 01; 8(4):330-4. PubMed ID: 7533640
    [Abstract] [Full Text] [Related]

  • 9. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.
    Shafer RW, Kozal MJ, Winters MA, Iversen AK, Katzenstein DA, Ragni MV, Meyer WA, Gupta P, Rasheed S, Coombs R.
    J Infect Dis; 1994 Apr 01; 169(4):722-9. PubMed ID: 8133086
    [Abstract] [Full Text] [Related]

  • 10. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years.
    Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, Merigan TC.
    Antimicrob Agents Chemother; 1997 Apr 01; 41(4):757-62. PubMed ID: 9087484
    [Abstract] [Full Text] [Related]

  • 11. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.
    Shafer RW, Iversen AK, Winters MA, Aguiniga E, Katzenstein DA, Merigan TC.
    J Infect Dis; 1995 Jul 01; 172(1):70-8. PubMed ID: 7541064
    [Abstract] [Full Text] [Related]

  • 12. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
    Sölder B, Wintergerst U, Notheis G, Eberle J, Gürtler L, Belohradsky BH.
    J Pediatr; 1997 Feb 01; 130(2):293-9. PubMed ID: 9042135
    [Abstract] [Full Text] [Related]

  • 13. Antiretroviral effect of zidovudine-didanosine combination on blood and lymph nodes.
    Lafeuillade A, Tamalet C, Poggi C, Pellegrino P, Tourres C, Izopet J.
    AIDS; 1997 Jan 01; 11(1):67-72. PubMed ID: 9110077
    [Abstract] [Full Text] [Related]

  • 14. Drug resistance mutations among HIV-1 strains from antiretroviral-naive patients in Martinique, French West Indies.
    Césaire R, Dos Santos G, Abel S, Bera O, Sobesky G, Cabié A.
    J Acquir Immune Defic Syndr; 1999 Dec 01; 22(4):401-5. PubMed ID: 10634203
    [Abstract] [Full Text] [Related]

  • 15. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.
    Coakley EP, Gillis JM, Hammer SM.
    AIDS; 2000 Jan 28; 14(2):F9-15. PubMed ID: 10708277
    [Abstract] [Full Text] [Related]

  • 16. Comparison of selective polymerase chain reaction primers and differential probe hybridization of polymerase chain reaction products for determination of relative amounts of codon 215 mutant and wild-type HIV-1 populations.
    Eastman PS, Urdea M, Besemer D, Stempien M, Kolberg J.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul 01; 9(3):264-73. PubMed ID: 7540490
    [Abstract] [Full Text] [Related]

  • 17. A pilot case-control study of zidovudine compared with zidovudine plus didanosine in patients with advanced HIV-1 disease and no previous experience with antiretrovirals.
    Gatell JM, Leal M, Mallolas J, Vidal C, Pumarola T, Parra R, Padró S, Caruz A, Falgueras T, Rey C, Sánchez-Quijano A, Torres Y, Lissen E, Jiménez de Anta MT, Soriano E.
    Antivir Ther; 1996 Apr 01; 1(2):105-12. PubMed ID: 11321180
    [Abstract] [Full Text] [Related]

  • 18. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA, Hughes MD, Liou SH, Katzenstein DA, Murphy R, Balfour HH, Para MF, Valdez H, Hammer SM, ACTG 303 Study Team.
    AIDS Res Hum Retroviruses; 2000 Sep 20; 16(14):1337-44. PubMed ID: 11018853
    [Abstract] [Full Text] [Related]

  • 19. Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy.
    Holodniy M, Katzenstein D, Winters M, Montoya J, Shafer R, Kozal M, Ragni M, Merigan TC.
    J Acquir Immune Defic Syndr (1988); 1993 Apr 20; 6(4):366-9. PubMed ID: 8095981
    [Abstract] [Full Text] [Related]

  • 20. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
    Brun-Vézinet F, Boucher C, Loveday C, Descamps D, Fauveau V, Izopet J, Jeffries D, Kaye S, Krzyanowski C, Nunn A, Schuurman R, Seigneurin JM, Tamalet C, Tedder R, Weber J, Weverling GJ.
    Lancet; 1997 Oct 04; 350(9083):983-90. PubMed ID: 9329513
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.